PubRank

William L Gerald

Author PubWeight™ 230.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Integrative genomic profiling of human prostate cancer. Cancer Cell 2010 23.61
2 Genes that mediate breast cancer metastasis to lung. Nature 2005 19.85
3 Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008 14.37
4 Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008 10.12
5 Genes that mediate breast cancer metastasis to the brain. Nature 2009 8.23
6 TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008 7.60
7 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004 6.95
8 Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005 6.10
9 Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009 5.31
10 Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007 5.17
11 Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004 4.59
12 Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002 4.42
13 Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005 4.20
14 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008 4.13
15 An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007 4.00
16 Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011 3.92
17 Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A 2007 3.84
18 Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 2005 3.79
19 WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009 3.76
20 A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006 3.37
21 Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006 3.32
22 Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008 3.30
23 The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008 2.87
24 ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A 2007 2.85
25 Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005 2.78
26 TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009 2.42
27 EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005 2.37
28 Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007 2.32
29 A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 2013 2.29
30 Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 2004 2.25
31 Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009 2.10
32 The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 2009 2.09
33 Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004 2.08
34 High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002 1.83
35 Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell 2002 1.80
36 Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 2006 1.78
37 Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011 1.74
38 Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009 1.72
39 Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res 2006 1.56
40 Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003 1.54
41 Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005 1.49
42 Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatr Blood Cancer 2005 1.45
43 Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 2008 1.42
44 MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One 2011 1.38
45 Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007 1.38
46 EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 2005 1.37
47 KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008 1.36
48 NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009 1.35
49 Identification of DOK genes as lung tumor suppressors. Nat Genet 2010 1.32
50 Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res 2003 1.24
51 TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010 1.23
52 Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res 2007 1.20
53 Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res 2004 1.20
54 Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer 2007 1.15
55 Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007 1.14
56 Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg 2006 1.10
57 The signatures of autozygosity among patients with colorectal cancer. Cancer Res 2008 1.10
58 Desmoplastic small cell tumor in the pancreas. Am J Surg Pathol 2004 1.08
59 Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev 2010 1.05
60 Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia 2005 1.01
61 Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med 2010 0.99
62 MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J 2011 0.98
63 The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther 2007 0.95
64 Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev 2003 0.95
65 Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 2006 0.94
66 Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance. Hum Pathol 2007 0.93
67 Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genet Cytogenet 2004 0.91
68 Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer 2009 0.91
69 Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res 2009 0.90
70 Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene 2002 0.90
71 Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography. J Clin Oncol 2008 0.89
72 Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Med Genomics 2008 0.86
73 Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis. PLoS One 2009 0.85
74 Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Res 2002 0.85
75 Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 2003 0.83
76 Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. Cancer 2002 0.82
77 Origin of neuroblastic tumors: clues for future therapeutics. Expert Rev Mol Diagn 2004 0.82
78 Genomic medicine and neuroblastoma. Expert Rev Mol Diagn 2003 0.81
79 Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma. Genes Chromosomes Cancer 2007 0.79
80 Comparison of normal and tumor cells by laser capture microdissection. Methods Enzymol 2002 0.76
81 The 2006 Fred Waldorf Stewart Award recipient Juan Rosai, MD. Am J Surg Pathol 2007 0.75